197 related articles for article (PubMed ID: 34193346)
1. First-line Daratumumab in Addition to Chemotherapy for Newly Diagnosed Multiple Myeloma Patients Who are Transplant Ineligible: A Cost-Effectiveness Analysis.
Li S; Li J; Peng L; Tan C; Zeng X; Peng C; Zhang C; Li Y; Wan X
Clin Ther; 2021 Jul; 43(7):1253-1264.e5. PubMed ID: 34193346
[TBL] [Abstract][Full Text] [Related]
2. Cost-Effectiveness Analysis of Adding Daratumumab to a Regimen of Bortezomib, Melphalan, and Prednisone in Newly Diagnosed Multiple Myeloma.
Zeng X; Liu Q; Peng L; Peng Y; Yi L; Luo X; Li S; Wan X; Tan C
Adv Ther; 2021 May; 38(5):2379-2390. PubMed ID: 33770365
[TBL] [Abstract][Full Text] [Related]
3. Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Standard of Care in Latin America for Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Propensity Score Matching Analysis.
Hungria V; Martínez-Baños DM; Mateos MV; Dimopoulos MA; Cavo M; Heeg B; Garcia A; Lam A; Machnicki G; He J; Fernandez M
Adv Ther; 2020 Dec; 37(12):4996-5009. PubMed ID: 33067698
[TBL] [Abstract][Full Text] [Related]
4. Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial.
Mateos MV; Cavo M; Blade J; Dimopoulos MA; Suzuki K; Jakubowiak A; Knop S; Doyen C; Lucio P; Nagy Z; Pour L; Cook M; Grosicki S; Crepaldi A; Liberati AM; Campbell P; Shelekhova T; Yoon SS; Iosava G; Fujisaki T; Garg M; Krevvata M; Chen Y; Wang J; Kudva A; Ukropec J; Wroblewski S; Qi M; Kobos R; San-Miguel J
Lancet; 2020 Jan; 395(10218):132-141. PubMed ID: 31836199
[TBL] [Abstract][Full Text] [Related]
5. Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Frailty Subgroup Analysis of ALCYONE.
Mateos MV; Dimopoulos MA; Cavo M; Suzuki K; Knop S; Doyen C; Lucio P; Nagy Z; Pour L; Grosicki S; Crepaldi A; Liberati AM; Campbell P; Yoon SS; Iosava G; Fujisaki T; Garg M; Iida S; Bladé J; Ukropec J; Pei H; Van Rampelbergh R; Kudva A; Qi M; San-Miguel J
Clin Lymphoma Myeloma Leuk; 2021 Nov; 21(11):785-798. PubMed ID: 34344638
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of lenalidomide plus dexamethasone vs. bortezomib plus melphalan and prednisone in transplant-ineligible U.S. patients with newly-diagnosed multiple myeloma.
Usmani SZ; Cavenagh JD; Belch AR; Hulin C; Basu S; White D; Nooka A; Ervin-Haynes A; Yiu W; Nagarwala Y; Berger A; Pelligra CG; Guo S; Binder G; Gibson CJ; Facon T
J Med Econ; 2016; 19(3):243-58. PubMed ID: 26517601
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of adding daratumumab or bortezomib to lenalidomide plus dexamethasone for newly diagnosed multiple myeloma.
Narsipur N; Bulla S; Yoo C; Do B; Tran K; Gu D; Zhong L; Wilson L
J Manag Care Spec Pharm; 2021 Dec; 27(12):1691-1702. PubMed ID: 34818089
[No Abstract] [Full Text] [Related]
8. Cost-Effectiveness Analysis of Adding Daratumumab to Bortezomib, Melphalan, and Prednisone for Untreated Multiple Myeloma.
Cao Y; Zhao L; Zhang T; Cao W
Front Pharmacol; 2021; 12():608685. PubMed ID: 33732154
[No Abstract] [Full Text] [Related]
9. Comparative Efficacy of Bortezomib, Melphalan, and Prednisone (VMP) With or Without Daratumumab Versus VMP Alone in the Treatment of Newly Diagnosed Multiple Myeloma: Propensity Score Matching of ALCYONE and VISTA Phase III Studies.
Cavo M; Dimopoulos MA; San-Miguel J; Mateos MV; Jakubowiak A; Deraedt W; Lam A; Kampfenkel T; Qi M; He J
Clin Lymphoma Myeloma Leuk; 2020 Jul; 20(7):480-489. PubMed ID: 32278674
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of Daratumumab-based Triplet Therapies in Patients With Relapsed or Refractory Multiple Myeloma.
Zhang TT; Wang S; Wan N; Zhang L; Zhang Z; Jiang J
Clin Ther; 2018 Jul; 40(7):1122-1139. PubMed ID: 30006069
[TBL] [Abstract][Full Text] [Related]
11. Cost-Effectiveness of Novel Agent Regimens for Transplant-Eligible Newly Diagnosed Multiple Myeloma Patients in India.
Dixit J; Malhotra P; Mehra N; Mathew A; Kumar L; Singh A; Gupta N; Krishnamurthy MN; Roy PS; Kataki AC; Gupta S; Prinja S
Appl Health Econ Health Policy; 2024 Jul; 22(4):569-582. PubMed ID: 38448720
[TBL] [Abstract][Full Text] [Related]
12. Bortezomib, Melphalan, and Prednisone With or Without Daratumumab in Transplant-ineligible Asian Patients With Newly Diagnosed Multiple Myeloma: The Phase 3 OCTANS Study.
Fu W; Bang SM; Huang H; Kim K; Li W; An G; Lee JJ; Cai Z; Jin J; Wang Y; Lin TL; Chim CS; Qi M; Wang J; Lu X; Song Y; Jia B; Yang X; Liu W; Zhou T; Yin L; Li Y; Zhang R; Hou J; Wang J
Clin Lymphoma Myeloma Leuk; 2023 Jun; 23(6):446-455.e4. PubMed ID: 37024420
[TBL] [Abstract][Full Text] [Related]
13. Economic Evaluation of Adding Daratumumab to a Regimen of Bortezomib + Dexamethasone in Relapsed or Refractory Multiple Myeloma: Based on the Latest Updated Analysis of CASTOR.
Zeng X; Peng L; Peng Y; Tan C; Wan X
Clin Ther; 2020 Feb; 42(2):251-262.e5. PubMed ID: 31973936
[TBL] [Abstract][Full Text] [Related]
14. Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE.
San-Miguel J; Avet-Loiseau H; Paiva B; Kumar S; Dimopoulos MA; Facon T; Mateos MV; Touzeau C; Jakubowiak A; Usmani SZ; Cook G; Cavo M; Quach H; Ukropec J; Ramaswami P; Pei H; Qi M; Sun S; Wang J; Krevvata M; DeAngelis N; Heuck C; Van Rampelbergh R; Kudva A; Kobos R; Qi M; Bahlis NJ
Blood; 2022 Jan; 139(4):492-501. PubMed ID: 34269818
[TBL] [Abstract][Full Text] [Related]
15. Cost-Effectiveness of First-Line Versus Second-Line Use of Daratumumab in Older, Transplant-Ineligible Patients With Multiple Myeloma.
Patel KK; Giri S; Parker TL; Bar N; Neparidze N; Huntington SF
J Clin Oncol; 2021 Apr; 39(10):1119-1128. PubMed ID: 33411586
[TBL] [Abstract][Full Text] [Related]
16. Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study.
Cavo M; Gay F; Beksac M; Pantani L; Petrucci MT; Dimopoulos MA; Dozza L; van der Holt B; Zweegman S; Oliva S; van der Velden VHJ; Zamagni E; Palumbo GA; Patriarca F; Montefusco V; Galli M; Maisnar V; Gamberi B; Hansson M; Belotti A; Pour L; Ypma P; Grasso M; Croockewit A; Ballanti S; Offidani M; Vincelli ID; Zambello R; Liberati AM; Andersen NF; Broijl A; Troia R; Pascarella A; Benevolo G; Levin MD; Bos G; Ludwig H; Aquino S; Morelli AM; Wu KL; Boersma R; Hajek R; Durian M; von dem Borne PA; Caravita di Toritto T; Zander T; Driessen C; Specchia G; Waage A; Gimsing P; Mellqvist UH; van Marwijk Kooy M; Minnema M; Mandigers C; Cafro AM; Palmas A; Carvalho S; Spencer A; Boccadoro M; Sonneveld P
Lancet Haematol; 2020 Jun; 7(6):e456-e468. PubMed ID: 32359506
[TBL] [Abstract][Full Text] [Related]
17. Daratumumab plus bortezomib, melphalan, and prednisone in East Asian patients with non-transplant multiple myeloma: subanalysis of the randomized phase 3 ALCYONE trial.
Fujisaki T; Ishikawa T; Takamatsu H; Suzuki K; Min CK; Lee JH; Wang J; Carson R; Crist W; Qi M; Nagafuji K
Ann Hematol; 2019 Dec; 98(12):2805-2814. PubMed ID: 31620815
[TBL] [Abstract][Full Text] [Related]
18. A matching-adjusted indirect treatment comparison (MAIC) of daratumumab-bortezomib-melphalan-prednisone (D-VMP) versus lenalidomide-dexamethasone continuous (Rd continuous), lenalidomide-dexamethasone 18 months (Rd 18), and melphalan-prednisone-thalidomide (MPT).
Dimopoulos MA; Cavo M; Mateos MV; Facon T; Heeg B; van Beekhuizen S; Gebregergish SB; Nair S; Pisini M; Lam A; Slavcev M
Leuk Lymphoma; 2020 Mar; 61(3):714-720. PubMed ID: 31686559
[TBL] [Abstract][Full Text] [Related]
19. Daratumumab: A Review in Combination Therapy for Transplant-Ineligible Newly Diagnosed Multiple Myeloma.
Syed YY
Drugs; 2019 Mar; 79(4):447-454. PubMed ID: 30830601
[TBL] [Abstract][Full Text] [Related]
20. The effects of different schedules of bortezomib, melphalan, and prednisone for patients with newly diagnosed multiple myeloma who are transplant ineligible: a matching-adjusted indirect comparison.
Mateos MV; San-Miguel J; Goldschmidt H; Sonneveld P; Dimopoulos MA; Heeg B; Hashim M; Deraedt W; Hu P; Lam A; He J
Leuk Lymphoma; 2020 Mar; 61(3):680-690. PubMed ID: 31686561
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]